Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Esperion Therapeutics

Nasdaq:ESPR
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ESPR
Nasdaq
$971M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). The last earnings update was 30 days ago. More info.


Add to Portfolio Compare Print
  • Esperion Therapeutics has significant price volatility in the past 3 months.
ESPR Share Price and Events
7 Day Returns
3.3%
NasdaqGM:ESPR
6.3%
US Biotechs
12.6%
US Market
1 Year Returns
-12.1%
NasdaqGM:ESPR
1.6%
US Biotechs
-9.1%
US Market
ESPR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Esperion Therapeutics (ESPR) 3.3% -32.5% -40.7% -12.1% -0.1% -64.6%
US Biotechs 6.3% -7.9% -7.9% 1.6% 7.7% -8.8%
US Market 12.6% -16.7% -19.6% -9.1% 8.2% 21.5%
1 Year Return vs Industry and Market
  • ESPR underperformed the Biotechs industry which returned 1.6% over the past year.
  • ESPR underperformed the Market in United States of America which returned -9.1% over the past year.
Price Volatility
ESPR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Esperion Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Esperion Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Esperion Therapeutics.

NasdaqGM:ESPR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:ESPR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.2
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.203 (1 + (1- 21%) (13.81%))
1.224
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.224 * 5.44%)
8.4%

Discounted Cash Flow Calculation for NasdaqGM:ESPR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Esperion Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:ESPR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.4%)
2020 -131.50 Analyst x2 -121.31
2021 -223.50 Analyst x2 -190.22
2022 160.00 Analyst x1 125.62
2023 206.64 Est @ 29.15% 149.67
2024 249.88 Est @ 20.93% 166.98
2025 287.79 Est @ 15.17% 177.41
2026 319.85 Est @ 11.14% 181.90
2027 346.47 Est @ 8.32% 181.78
2028 368.46 Est @ 6.35% 178.34
2029 386.75 Est @ 4.96% 172.69
Present value of next 10 years cash flows $1,022.00
NasdaqGM:ESPR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $386.75 × (1 + 1.74%) ÷ (8.4% – 1.74%)
$5,911.05
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,911.05 ÷ (1 + 8.4%)10
$2,639.39
NasdaqGM:ESPR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,022.00 + $2,639.39
$3,661.39
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,661.39 / 27.51
$133.08
NasdaqGM:ESPR Discount to Share Price
Calculation Result
Value per share (USD) From above. $133.08
Current discount Discount to share price of $35.29
= -1 x ($35.29 - $133.08) / $133.08
73.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Esperion Therapeutics is available for.
Intrinsic value
>50%
Share price is $35.29 vs Future cash flow value of $133.08
Current Discount Checks
For Esperion Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Esperion Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Esperion Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Esperion Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Esperion Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:ESPR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.59
NasdaqGM:ESPR Share Price ** NasdaqGM (2020-03-27) in USD $35.29
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.87x
United States of America Market PE Ratio Median Figure of 2,935 Publicly-Listed Companies 13.38x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Esperion Therapeutics.

NasdaqGM:ESPR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ESPR Share Price ÷ EPS (both in USD)

= 35.29 ÷ -3.59

-9.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Esperion Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Esperion Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Esperion Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:ESPR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -9.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
14.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.99x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1.03x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Esperion Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Esperion Therapeutics's assets?
Raw Data
NasdaqGM:ESPR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.73
NasdaqGM:ESPR Share Price * NasdaqGM (2020-03-27) in USD $35.29
United States of America Biotechs Industry PB Ratio Median Figure of 428 Publicly-Listed Biotechs Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,145 Publicly-Listed Companies 1.27x
NasdaqGM:ESPR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ESPR Share Price ÷ Book Value per Share (both in USD)

= 35.29 ÷ 0.73

48.64x

* Primary Listing of Esperion Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Esperion Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Esperion Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Esperion Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Esperion Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Esperion Therapeutics expected to grow at an attractive rate?
  • Esperion Therapeutics's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Esperion Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Esperion Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:ESPR Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:ESPR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 14.6%
NasdaqGM:ESPR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 28%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:ESPR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:ESPR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 676 225 156 2
2023-12-31 272 -203 -218 2
2022-12-31 621 -47 -34 6
2021-12-31 209 -241 -224 9
2020-12-31 220 -154 -203 9
2020-03-28
NasdaqGM:ESPR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 148 -70 -97
2019-09-30 147 -49 -95
2019-06-30 146 -29 -77
2019-03-31 145 -14 -68
2018-12-31 -149 -202
2018-09-30 -155 -180
2018-06-30 -153 -175
2018-03-31 -140 -173
2017-12-31 -131 -167
2017-09-30 -113 -158
2017-06-30 -91 -130
2017-03-31 -72 -101

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Esperion Therapeutics's earnings are expected to grow by 14.6% yearly, however this is not considered high growth (20% yearly).
  • Esperion Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:ESPR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from Esperion Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ESPR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 4.64 6.09 3.19 2.00
2023-12-31 -6.73 -6.01 -7.45 2.00
2022-12-31 -1.58 7.03 -9.68 3.00
2021-12-31 -7.57 1.49 -11.85 8.00
2020-12-31 -7.39 -4.98 -8.47 8.00
2020-03-28
NasdaqGM:ESPR Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.59
2019-09-30 -3.53
2019-06-30 -2.86
2019-03-31 -2.55
2018-12-31 -7.54
2018-09-30 -6.75
2018-06-30 -6.73
2018-03-31 -6.92
2017-12-31 -6.98
2017-09-30 -6.87
2017-06-30 -5.77
2017-03-31 -4.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Esperion Therapeutics is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Esperion Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Esperion Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Esperion Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Esperion Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Esperion Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Esperion Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Esperion Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Esperion Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Esperion Therapeutics Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:ESPR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 148.36 -97.17 65.85
2019-09-30 147.38 -95.26 55.32 171.49
2019-06-30 146.40 -76.79 45.86 171.49
2019-03-31 145.42 -68.30 39.33 171.49
2018-12-31 -201.81 33.10
2018-09-30 -179.66 27.18 33.44
2018-06-30 -174.97 23.85 73.50
2018-03-31 -172.58 22.30 111.74
2017-12-31 -166.99 21.38
2017-09-30 -158.05 20.53 139.05
2017-06-30 -130.24 19.06 112.49
2017-03-31 -100.93 18.28 83.94
2016-12-31 -74.98 18.28 57.87
2016-09-30 -59.14 19.16 40.94
2016-06-30 -54.54 20.61 34.69
2016-03-31 -52.90 21.23 32.20
2015-12-31 -49.78 20.24 29.80
2015-09-30 -46.12 18.14 28.05
2015-06-30 -43.12 14.99 27.97
2015-03-31 -39.97 12.47 27.29
2014-12-31 -36.38 10.92 25.30
2014-09-30 -36.61 10.14 26.44
2014-06-30 -32.04 9.54 22.75
2014-03-31 -29.72 7.98 19.32
2013-12-31 -26.09 6.75 16.01
2013-09-30 -19.17 4.85 10.33
2013-06-30 -17.29 3.46 9.30
2013-03-31 -13.53 2.82 8.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Esperion Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Esperion Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Esperion Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Esperion Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Esperion Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Esperion Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Esperion Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Esperion Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Esperion Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Esperion Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Esperion Therapeutics Company Filings, last reported 2 months ago.

NasdaqGM:ESPR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 19.95 132.54 200.78
2019-09-30 68.51 128.42 243.86
2019-06-30 129.33 124.41 301.23
2019-03-31 175.01 0.00 228.53
2018-12-31 79.12 0.00 136.02
2018-09-30 131.75 0.00 159.22
2018-06-30 175.92 0.15 180.17
2018-03-31 214.14 0.60 197.22
2017-12-31 244.69 1.05 200.20
2017-09-30 278.10 1.48 203.37
2017-06-30 154.11 1.90 167.41
2017-03-31 192.42 2.32 181.88
2016-12-31 228.60 2.73 211.58
2016-09-30 254.18 3.13 210.10
2016-06-30 267.96 3.53 207.18
2016-03-31 277.76 3.91 194.47
2015-12-31 287.26 4.29 212.26
2015-09-30 296.48 4.66 215.60
2015-06-30 305.46 4.90 224.78
2015-03-31 314.43 4.89 278.11
2014-12-31 133.55 4.87 105.84
2014-09-30 50.22 4.93 52.96
2014-06-30 58.91 4.92 59.72
2014-03-31 67.04 0.00 56.70
2013-12-31 74.09 0.00 60.06
2013-09-30 83.23 0.00 71.90
2013-06-30 12.89 0.00 16.63
2013-03-31 19.74 0.00 20.89
  • Esperion Therapeutics's level of debt (664.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (3.6% vs 664.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Esperion Therapeutics has sufficient cash runway for 2.8 years based on current free cash flow.
  • Esperion Therapeutics has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 21.4% each year.
X
Financial health checks
We assess Esperion Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Esperion Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Esperion Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Esperion Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Esperion Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Esperion Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Esperion Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:ESPR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:ESPR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 2.00
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Esperion Therapeutics has not reported any payouts.
  • Unable to verify if Esperion Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Esperion Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Esperion Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Esperion Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Esperion Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Esperion Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Esperion Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Esperion Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Tim Mayleben
COMPENSATION $9,724,839
AGE 58
TENURE AS CEO 7.3 years
CEO Bio

Mr. Timothy M. Mayleben, also known as Tim, M.B.A., has been the Chief Executive Officer and President of Esperion Therapeutics, Inc. since December 2012. Mr. Mayleben serves as an Advisor to several biotechnology companies in the Ann Arbor area. Mr. Mayleben serves as the President of ElMa Advisors, LLC. He served as the Chief Operating Officer and Executive Vice President of Nighthawk Radiology Services, LLC since January 2007. Mr. Mayleben served as the Chief Operating Officer of original Esperion, Inc., from April 2002 to 2004 and served as its Chief Financial Officer since January 1999. He joined Esperion in 1998 and was responsible for raising more than $200 million in venture capital and institutional equity funding and negotiated the acquisition of Esperion by Pfizer in 2004. He also served as Senior Vice President of Operations and Finance at Esperion from January 2002 to April 2002 and served as its Vice President of Finance from January 1999 to January 2002. He served as the Chief Executive Officer and President of Aastrom Biosciences Inc. (alternate name Vericel Corporation) since December 14, 2009 until December 14, 2012. He served as the President of NightHawk Radiology Holdings, Inc. since July 25, 2007 and served as its Chief Operating Officer and Executive Vice President from January 8, 2007 to July 25, 2007. Mr. Mayleben served as the Chief Executive Officer and President of Alba Therapeutics Corporation and served as its Chief Financial Officer and Chief Operating Officer. He served as the Chief Financial Officer of Aastrom Biosciences Inc. from December 14, 2009 to June 7, 2010. Mr. Mayleben served as a Consultant with ElMa and has been in advising life science and health care companies since 2004. Mr. Mayleben served as the Director of Business Development for Engineering Animation Inc. from September 1998 to December 1998. From July 1997 to September 1998, he served as the Chief Operating Officer and Chief Financial Officer of Transom Technologies Inc. He raised capital and co-led the negotiations for the sale of Transom to EDS. From September 1990 to July 1997, he served in various managerial positions including as the Director of Operations of Applied Intelligent Systems Inc. Mr. Mayleben served as a Manager with the Enterprise Group of Arthur Andersen & Co. He started his professional career with an international public accounting firm in 1984. Mr. Mayleben serves as a Director for several private life science companies. He has been a Director of Esperion Therapeutics, Inc. since February 2010. He serves as a Member of the Advisory Board at The Wolverine Venture Fund, L.P. He was a Director of Loxo Oncology, Inc. since July 30, 2015 until February 15, 2019. He serves as a Director of kaleo, Inc., and DeNovo Sciences. He has been an Independent Director of Marinus Pharmaceuticals, Inc. since December 2008 and had been its Lead Independent Director since 2017 until 2019. Mr. Mayleben served as a Director of Nighthawk Radiology Services, LLC since 2005. Mr. Mayleben served as a Director of Lycera Corp. until March 13, 2017. Mr. Mayleben served as a Director of Aastrom Biosciences, Inc. since June 20, 2005. He served as a Director of Rubicon Genomics, Inc. He served as a Director of Nighthawk Radiology Holdings Inc. since March 2005 and Advanced ICU Care, Inc. since November 2006. Mr. Mayleben also served as a Member of the Board of Directors at Coputer Challenge Inc. He served as a Director of Aksys Ltd. since June 23, 2006. He served as a Member of Advisory Board at Alba Therapeutics Corporation. Mr. Mayleben has more than a decade of executive leadership roles in the life sciences industry. He is also an advisor to, investor in, and member of the board of directors of several life science companies. He is also an active angel investor in Michigan life sciences companies. Mr. Mayleben has an M.B.A. with distinction from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.B.A. from the University Of Michigan, Ross School Of Business.

CEO Compensation
  • Tim's compensation has increased whilst company is loss making.
  • Tim's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Esperion Therapeutics management team in years:

1.9
Average Tenure
53
Average Age
  • The average tenure for the Esperion Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Tim Mayleben

TITLE
President
COMPENSATION
$10M
AGE
58
TENURE
7.3 yrs

Rick Bartram

TITLE
CFO & Corporate Secretary
COMPENSATION
$3M
AGE
37
TENURE
2.2 yrs

Mark Glickman

TITLE
Chief Commercial Officer
COMPENSATION
$9M
AGE
53
TENURE
1.9 yrs

Ken Fiorelli

TITLE
Chief Technical Operations Officer
TENURE
0.5 yrs

Alex Schwartz

TITLE
Senior Director of Investor Relations
TENURE
1.8 yrs

Regina Cavaliere

TITLE
Chief Ethics & Compliance Officer
TENURE
0.7 yrs

Keith Lenden

TITLE
Vice President of Corporate Development & Strategy
AGE
46

Renee Marotta

TITLE
Head of Marketing

Ashley Hall

TITLE
Chief Development Officer
TENURE
1.9 yrs

Bill Sasiela

TITLE
Senior Vice President of Clinical Development
AGE
53
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the Esperion Therapeutics board of directors in years:

5.2
Average Tenure
61
Average Age
  • The tenure for the Esperion Therapeutics board of directors is about average.
Board of Directors

Nicole Vitullo

TITLE
Lead Independent Director
COMPENSATION
$312K
AGE
62
TENURE
4.3 yrs

Tim Mayleben

TITLE
President
COMPENSATION
$10M
AGE
58
TENURE
10.1 yrs

Jay Shepard

TITLE
Independent Director
COMPENSATION
$477K
AGE
61
TENURE
1.8 yrs

Alan Fuhrman

TITLE
Independent Non-Employee Director
AGE
62

Antonio Gotto

TITLE
Independent Director
COMPENSATION
$291K
AGE
84
TENURE
6.2 yrs

Dan Janney

TITLE
Independent Director
COMPENSATION
$271K
AGE
54
TENURE
7.3 yrs

Mark McGovern

TITLE
Independent Director
COMPENSATION
$287K
AGE
66
TENURE
6.1 yrs

Jeff Berkowitz

TITLE
Director
COMPENSATION
$1M
AGE
53
TENURE
2.3 yrs

Tracy Woody

TITLE
Director
AGE
49
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Esperion Therapeutics individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Mar 20 Buy Timothy Mayleben Individual 11. Mar 20 11. Mar 20 2,500 $43.00 $107,500
02. Mar 20 Buy Timothy Mayleben Individual 28. Feb 20 28. Feb 20 5,000 $49.00 $245,000
27. Jan 20 Buy Bellevue Asset Management AG Company 23. Jan 20 23. Jan 20 20,000 $52.12 $1,042,398
08. Nov 19 Buy Timothy Mayleben Individual 06. Nov 19 06. Nov 19 5,000 $36.98 $184,900
08. Nov 19 Buy Bellevue Asset Management AG Company 06. Nov 19 06. Nov 19 75,000 $37.30 $2,797,560
06. Sep 19 Buy Bellevue Asset Management AG Company 04. Sep 19 04. Sep 19 80,000 $33.78 $2,702,208
06. Sep 19 Buy Timothy Mayleben Individual 04. Sep 19 06. Sep 19 7,500 $35.25 $259,107
02. Aug 19 Buy Timothy Mayleben Individual 01. Aug 19 01. Aug 19 5,000 $39.56 $197,800
25. Jul 19 Buy Bellevue Asset Management AG Company 23. Jul 19 23. Jul 19 50,000 $42.65 $2,132,565
01. Jul 19 Buy Timothy Mayleben Individual 28. Jun 19 28. Jun 19 5,000 $46.00 $230,000
01. Apr 19 Buy Timothy Mayleben Individual 29. Mar 19 29. Mar 19 5,000 $40.00 $200,000
X
Management checks
We assess Esperion Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Esperion Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Introducing Esperion Therapeutics (NASDAQ:ESPR), The Stock That Zoomed 245% In The Last Three Years

See our latest analysis for Esperion Therapeutics Because Esperion Therapeutics is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … If you are thinking of buying or selling Esperion Therapeutics stock, you should check out this free report showing analyst profit forecasts. … You can find out about the insider purchases of Esperion Therapeutics by clicking this link.

Simply Wall St -

How Much Are Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Spending On Buying Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Esperion Therapeutics, Inc. … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for Esperion Therapeutics The Last 12 Months Of Insider Transactions At Esperion Therapeutics In the last twelve months, the biggest single purchase by an insider was when President Timothy Mayleben bought US$244k worth of shares at a price of US$48.73 per share. … When combined with notable insider ownership, these factors suggest Esperion Therapeutics insiders are well aligned, and that they may think the share price is too low.

Simply Wall St -

Esperion Therapeutics, Inc. (NASDAQ:ESPR): What Does Its Beta Value Mean For Your Portfolio?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … What this means for you: Since Esperion Therapeutics has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

Can You Imagine How Chuffed Esperion Therapeutics's (NASDAQ:ESPR) Shareholders Feel About Its 190% Share Price Gain?

But on a lighter note, a good company can see its share price rise well over 100%. … With zero revenue generated over twelve months, we don't think that Esperion Therapeutics has proved its business plan yet. … Given how low on cash the it got, investors must really like its potential for the share price to be up 24% per year, over 5 years.

Simply Wall St -

Esperion Therapeutics, Inc. (NASDAQ:ESPR): Is It A Good Long Term Opportunity?

Esperion Therapeutics, Inc.'s (NASDAQ:ESPR) most recent earnings update in December 2018 … company earnings became less negative compared to the previous year's level … as a result of recent tailwinds

Simply Wall St -

Esperion Therapeutics Inc (NASDAQ:ESPR): Are Analysts Optimistic?

Esperion Therapeutics Inc's (NASDAQ:ESPR):. … With the latest financial year loss of -US$166.99m and a trailing-twelve month of -US$172.58m, the US$1.07b market-cap amplifies its loss by moving further away from its breakeven target. … I’ve put together a brief outline of industry analyst expectations for ESPR, its year of breakeven and its implied growth rate.

Simply Wall St -

Esperion Therapeutics Inc (NASDAQ:ESPR): Poised For Long-Term Success?

The latest earnings release Esperion Therapeutics Inc's (NASDAQ:ESPR) announced in December 2017 showed company earnings became less negative compared to the previous year's level - great news for investors Below is a brief commentary on my key takeaways on how market analysts view Esperion Therapeutics's earnings growth outlook over the next few years and whether the future looks brighter. … Check out our latest analysis for Esperion Therapeutics Market analysts' consensus outlook for next year seems positive, with earnings becoming less negative, arriving at -US$148.05M in 2019. … This means, we can anticipate Esperion Therapeutics will grow its earnings by 1.41% every year for the next few years.

Simply Wall St -

What Investors Should Know About Esperion Therapeutics Inc's (NASDAQ:ESPR) Financial Strength

See our latest analysis for Esperion Therapeutics Does ESPR generate enough cash through operations? … The good news for investors is that Esperion Therapeutics has virtually no debt. … Next Steps: ESPR’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.

Simply Wall St -

Should You Worry About Esperion Therapeutics Inc's (NASDAQ:ESPR) CEO Pay Check?

Therefore I will use earnings as a proxy of Mayleben's performance in the past year. … Most recently, ESPR produced negative earnings of -US$158.05M , which is a further decline from prior year's loss of -US$59.14M. … Normally I would look at market cap and earnings as a proxy for performance, however, ESPR's negative earnings reduces the effectiveness of this method.

Simply Wall St -

Should You Be Concerned About Esperion Therapeutics Inc's (NASDAQ:ESPR) Shareholders?

View our latest analysis for Esperion Therapeutics NasdaqGM:ESPR Ownership_summary Dec 22nd 17 Institutional Ownership In ESPR's case, institutional ownership stands at 98.25%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … We should dig deeper into the company's ownership structure to find how the rest of its ownership structure can impact its investment case. … However, if you are building an investment case for ESPR, ownership structure alone should not dictate your decision to buy or sell the stock.

Simply Wall St -

Company Info

Description

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.

Details
Name: Esperion Therapeutics, Inc.
ESPR
Exchange: NasdaqGM
Founded: 2008
$970,914,042
27,512,441
Website: http://www.esperion.com
Address: Esperion Therapeutics, Inc.
3891 Ranchero Drive,
Suite 150,
Ann Arbor,
Michigan, 48108,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ESPR Common Stock Nasdaq Global Market US USD 26. Jun 2013
DB 0ET Common Stock Deutsche Boerse AG DE EUR 26. Jun 2013
LSE 0IIM Common Stock London Stock Exchange GB USD 26. Jun 2013
BRSE 0ET Common Stock Berne Stock Exchange CH CHF 26. Jun 2013
Number of employees
Current staff
Staff numbers
193
Esperion Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 02:50
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/02/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.